Position in URGN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$23,627,733
+$5,322,193 QoQ
Shares Held
1,314,112
+68.1% QoQ
Ownership
2.70%
of shares outstanding
% of Portfolio
0.24%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2025
2 quarters on record
Voting authority
Sole 72%
Shared 0%
None 28%
Common Shares in URGN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026FRONTIER CAPITAL MANAGEMENT CO LLC holds $713,801,776 across 19 Biotechnology names. URGN ranks #12 (3.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JAZZ |
Jazz Pharmaceuticals plc
|
517,284 | $97,792,540 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
1,064,483 | $89,597,534 | |
| 3 | INSM |
INSMED Inc
|
469,561 | $76,782,614 | |
| 4 | BBIO |
BridgeBio Pharma, Inc.
|
957,989 | $71,140,263 | |
| 5 | KYMR |
Kymera Therapeutics, Inc.
|
759,848 | $63,287,739 | |
| 6 | PVLA |
Palvella Therapeutics, Inc.
|
374,035 | $46,623,462 | |
| 7 | RARE |
Ultragenyx Pharmaceutical Inc.
|
2,191,182 | $45,905,262 | |
| 8 | NUVL |
Nuvalent, Inc.
|
395,546 | $40,523,687 |
All Filings in URGN
Export CSV
2 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $23,627,733 | 1,314,112 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $18,305,540 | 781,620 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||